These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 16575727)

  • 1. Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya.
    Bejon P; Peshu N; Gilbert SC; Lowe BS; Molyneux CS; Forsdyke J; Lang T; Hill AV; Marsh K
    Clin Infect Dis; 2006 Apr; 42(8):1102-10. PubMed ID: 16575727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area.
    Bejon P; Mwacharo J; Kai OK; Todryk S; Keating S; Lang T; Gilbert SC; Peshu N; Marsh K; Hill AV
    Vaccine; 2006 May; 24(22):4709-15. PubMed ID: 16621181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.
    Moorthy VS; Imoukhuede EB; Keating S; Pinder M; Webster D; Skinner MA; Gilbert SC; Walraven G; Hill AV
    J Infect Dis; 2004 Jun; 189(12):2213-9. PubMed ID: 15181568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses.
    Prieur E; Gilbert SC; Schneider J; Moore AC; Sheu EG; Goonetilleke N; Robson KJ; Hill AV
    Proc Natl Acad Sci U S A; 2004 Jan; 101(1):290-5. PubMed ID: 14694197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternating vector immunizations encoding pre-erythrocytic malaria antigens enhance memory responses in a malaria endemic area.
    Bejon P; Kai OK; Mwacharo J; Keating S; Lang T; Gilbert SC; Peshu N; Marsh K; Hill AV
    Eur J Immunol; 2006 Aug; 36(8):2264-72. PubMed ID: 16856208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.
    Moorthy VS; Pinder M; Reece WH; Watkins K; Atabani S; Hannan C; Bojang K; McAdam KP; Schneider J; Gilbert S; Hill AV
    J Infect Dis; 2003 Oct; 188(8):1239-44. PubMed ID: 14551895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers.
    Webster DP; Dunachie S; McConkey S; Poulton I; Moore AC; Walther M; Laidlaw SM; Peto T; Skinner MA; Gilbert SC; Hill AV
    Vaccine; 2006 Apr; 24(15):3026-34. PubMed ID: 16488059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modified-vaccinia-virus-Ankara (MVA) priming and fowlpox-virus booster elicit a stronger CD8+ T-cell response in mice against an HIV-1 epitope than does a DNA/poxvirus prime-booster approach.
    Vázquez-Blomquist D; Quintana D; Duarte CA
    Biotechnol Appl Biochem; 2004 Jun; 39(Pt 3):313-8. PubMed ID: 15154843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men.
    Imoukhuede EB; Berthoud T; Milligan P; Bojang K; Ismaili J; Keating S; Nwakanma D; Keita S; Njie F; Sowe M; Todryk S; Laidlaw SM; Skinner MA; Lang T; Gilbert S; Greenwood BM; Hill AV
    Vaccine; 2006 Oct; 24(42-43):6526-33. PubMed ID: 16842888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
    McConkey SJ; Reece WH; Moorthy VS; Webster D; Dunachie S; Butcher G; Vuola JM; Blanchard TJ; Gothard P; Watkins K; Hannan CM; Everaere S; Brown K; Kester KE; Cummings J; Williams J; Heppner DG; Pathan A; Flanagan K; Arulanantham N; Roberts MT; Roy M; Smith GL; Schneider J; Peto T; Sinden RE; Gilbert SC; Hill AV
    Nat Med; 2003 Jun; 9(6):729-35. PubMed ID: 12766765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption.
    Harrer E; Bäuerle M; Ferstl B; Chaplin P; Petzold B; Mateo L; Handley A; Tzatzaris M; Vollmar J; Bergmann S; Rittmaier M; Eismann K; Müller S; Kalden JR; Spriewald B; Willbold D; Harrer T
    Antivir Ther; 2005; 10(2):285-300. PubMed ID: 15865223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus.
    Anderson RJ; Hannan CM; Gilbert SC; Laidlaw SM; Sheu EG; Korten S; Sinden R; Butcher GA; Skinner MA; Hill AV
    J Immunol; 2004 Mar; 172(5):3094-100. PubMed ID: 14978115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response.
    Ramos I; Alonso A; Marcen JM; Peris A; Castillo JA; Colmenares M; Larraga V
    Vaccine; 2008 Jan; 26(3):333-44. PubMed ID: 18093705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
    Hodge JW; Poole DJ; Aarts WM; Gómez Yafal A; Gritz L; Schlom J
    Cancer Res; 2003 Nov; 63(22):7942-9. PubMed ID: 14633725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.
    Hodgson SH; Ewer KJ; Bliss CM; Edwards NJ; Rampling T; Anagnostou NA; de Barra E; Havelock T; Bowyer G; Poulton ID; de Cassan S; Longley R; Illingworth JJ; Douglas AD; Mange PB; Collins KA; Roberts R; Gerry S; Berrie E; Moyle S; Colloca S; Cortese R; Sinden RE; Gilbert SC; Bejon P; Lawrie AM; Nicosia A; Faust SN; Hill AV
    J Infect Dis; 2015 Apr; 211(7):1076-86. PubMed ID: 25336730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1.
    Ranasinghe C; Medveczky JC; Woltring D; Gao K; Thomson S; Coupar BE; Boyle DB; Ramsay AJ; Ramshaw IA
    Vaccine; 2006 Jul; 24(31-32):5881-95. PubMed ID: 16759767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress in DNA-based heterologous prime-boost immunization strategies for malaria.
    Moore AC; Hill AV
    Immunol Rev; 2004 Jun; 199():126-43. PubMed ID: 15233731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines.
    Miao J; Li X; Liu Z; Xue C; Bujard H; Cui L
    Vaccine; 2006 Sep; 24(37-39):6187-98. PubMed ID: 16806600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults.
    Moorthy VS; Imoukhuede EB; Milligan P; Bojang K; Keating S; Kaye P; Pinder M; Gilbert SC; Walraven G; Greenwood BM; Hill AS
    PLoS Med; 2004 Nov; 1(2):e33. PubMed ID: 15526058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
    Ogwang C; Afolabi M; Kimani D; Jagne YJ; Sheehy SH; Bliss CM; Duncan CJ; Collins KA; Garcia Knight MA; Kimani E; Anagnostou NA; Berrie E; Moyle S; Gilbert SC; Spencer AJ; Soipei P; Mueller J; Okebe J; Colloca S; Cortese R; Viebig NK; Roberts R; Gantlett K; Lawrie AM; Nicosia A; Imoukhuede EB; Bejon P; Urban BC; Flanagan KL; Ewer KJ; Chilengi R; Hill AV; Bojang K
    PLoS One; 2013; 8(3):e57726. PubMed ID: 23526949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.